Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sino BiopharmaceuticalSBMFF 61 ROC (Joel Greenblatt) % is 22.52% as of Dec. 2025, which is 74% below its 10-year median of 86.38. GuruFocus rates SBMFF with a GF Score™ of 61/100 and a GF Value™ of $0.68 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,324 Biotechnology companies, Sino Biopharmaceutical ranks better than 93.66% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Sino Biopharmaceutical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 22.52%.
The historical rank and industry rank for Sino Biopharmaceutical's ROC (Joel Greenblatt) % or its related term are showing as below:
SBMFF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 54.52 Med: 86.38 Max: 234.38
Current: 71.28
During the past 13 years, Sino Biopharmaceutical's highest ROC (Joel Greenblatt) % was 234.38%. The lowest was 54.52%. And the median was 86.38%.
SBMFF's ROC (Joel Greenblatt) % is ranked better than 93.66% of 1324
companies
in the Biotechnology industry
Industry Median: -297.95
vs SBMFF: 71.28
Sino Biopharmaceutical's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -11.90% per year.
Sino Biopharmaceutical (OTCPK:SBMFF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Sino Biopharmaceutical ROC (Joel Greenblatt) % Related Terms
Sino Biopharmaceutical ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Sino Biopharmaceutical's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sino Biopharmaceutical ROC (Joel Greenblatt) % Chart
SBMFF vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Sino Biopharmaceutical's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's ROC (Joel Greenblatt) % falls into.
Sino Biopharmaceutical ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 22.52% mean?
Sino Biopharmaceutical (SBMFF) has a ROC (Joel Greenblatt) % of 22.52% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sino Biopharmaceutical and its competitors. This is 74% below median its historical median of 86.38. Over the past decade, Sino Biopharmaceutical's ROC (Joel Greenblatt) % has ranged from 54.52 to 234.38. According to the industry distribution chart, Sino Biopharmaceutical ranks #84 out of 1324 companies in the Biotechnology industry, placing it in the top 6.3%.
Is Sino Biopharmaceutical's ROC (Joel Greenblatt) % too high?
Sino Biopharmaceutical's current ROC (Joel Greenblatt) % of 22.52% is 74% below median its 10-year median of 86.38. Over the past 10 years, this metric has ranged from a low of 54.52 to a high of 234.38. Based on the distribution chart, Sino Biopharmaceutical ranks #84 out of 1324 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sino Biopharmaceutical has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #84 out of 1324 companies for ROC (Joel Greenblatt) %. This places Sino Biopharmaceutical in the top 6% of its industry — outperforming the majority of peers. Historically, Sino Biopharmaceutical's own ROC (Joel Greenblatt) % has ranged from 54.52 to 234.38 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sino Biopharmaceutical and its competitors. Sino Biopharmaceutical's current ROC (Joel Greenblatt) % is 22.52%, which is 74% below median its own 10-year median of 86.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Fairly Valued. The stock's GF Value™ is $0.68, compared to a current price of $0.64 — trading 6.3% below its estimated fair value. The current ROC (Joel Greenblatt) % is 22.52%, which is 74% below median its 10-year median of 86.38. Sino Biopharmaceutical's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current ROC (Joel Greenblatt) % is 22.52% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be undervalued.
The current stock price of $0.64 is trading 6.3% below its estimated GF Value™ of $0.68.
GuruFocus considers Sino Biopharmaceutical to be Fairly Valued.
Key valuation signals for SBMFF:
ROC (Joel Greenblatt) %: 22.52% (74% below median its 10-year median of 86.38)
GF Value™: $0.68 vs. price of $0.64 (6.3% below fair value)
No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
61GF Score
Get the complete analysis for SBMFF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBMFF has been successfully added to your 
